APA (7th ed.) Citation

J, F., L, S., T, M., T, P., J, S., C, B., & F, S. (2026). Prognostic value of [18F]FDG PET/CT and PERCIST criteria in patients with HER2-low metastatic breast cancer treated with trastuzumab deruxtecan. European journal of nuclear medicine and molecular imaging. https://doi.org/10.1007/s00259-026-08029-4

Chicago Style (17th ed.) Citation

J, Frega, Somme L, Martin T, Petit T, Salvadori J, Bund C, and Somme F. "Prognostic Value of [18F]FDG PET/CT and PERCIST Criteria in Patients with HER2-low Metastatic Breast Cancer Treated with Trastuzumab Deruxtecan." European Journal of Nuclear Medicine and Molecular Imaging 2026. https://doi.org/10.1007/s00259-026-08029-4.

MLA (9th ed.) Citation

J, Frega, et al. "Prognostic Value of [18F]FDG PET/CT and PERCIST Criteria in Patients with HER2-low Metastatic Breast Cancer Treated with Trastuzumab Deruxtecan." European Journal of Nuclear Medicine and Molecular Imaging, 2026, https://doi.org/10.1007/s00259-026-08029-4.